Palla Pharma Limited announced that it has formally launched its Co-Codamol 30/500 caplet in the UK market. This product is the first to be launched by Palla Pharma after receipt of the final approvals of its Marketing Authorisation (MA) by the MHRA in late February. The response from customers in the UK market has been very positive. Further products will follow over the coming months with a co-dydramol finished dose formulation expected to be launched in third quarter based upon receipt of all necessary regulatory approvals in accordance with normal approval timelines. The registration, validation, and approval processes for the other 5 Marketing Authorisations owned by Palla Pharma are on-going and updates will be provided in due course.